Overview of Primor

Quick Facts

Property	Description
Active Ingredients	Sulfadimethoxine, Ormetoprim
Form	Scored Tablets (Oral Dose)
Pharmacological Class	Potentiated Sulfonamide (Combination Antibiotic)
General Purpose	Broad-spectrum antiinfective activity
Origin	Synthetic (Chemically Synthesized)

What Type of Medicine is Primor?

Primor is a prescription-only antiinfective agent used in veterinary medicine, specifically classified as a potentiated sulfonamide or combination antibiotic. The drug is a synthetic compound that provides systemically active action following oral administration. This pharmacological classification indicates that Primor utilizes a strategy to boost the effect of one of its primary components, a method that is clinically recognized for delivering a superior outcome compared to single-drug formulations. Its veterinary focus and prescription status, restricted solely to the order of a licensed veterinarian, differentiates its clinical use from human-grade antimicrobial drugs.

Composition and Physical Form of Primor

Primor is a combination product that contains two distinct active ingredients: the sulfonamide Sulfadimethoxine and the diaminopyrimidine Ormetoprim. These substances are formulated into an oral dose delivered as scored tablets and are combined in a precise 5:1 ratio of Sulfadimethoxine to Ormetoprim, which is integral to the drug’s effectiveness. The combination is designed to interrupt the bacterial production of folic acid. The ability to accurately break the scored tablets is a key feature in facilitating flexible administration as determined by the veterinary professional.

The General Purpose of This Combination Antibiotic

The general purpose of Primor is to utilize its combined strength to achieve broad-spectrum antibacterial activity against susceptible pathogens. By executing a coordinated sequential blockade on the pathogen’s metabolism, the drug effectively stops the growth and reproduction of offending organisms. This robust action makes it a reliable antiinfective agent for systemic use.

Regulatory References

FDA FOI Summary for Primor (NADA 100-929)

What side effects are possible with Primor?

Possible Side Effects and Safety Information

The safety profile of Primor, a potentiated sulfonamide combination, is defined by adverse reactions classified across several physiological systems as documented in regulatory sources.

Official Adverse Reaction Listings

Adverse reactions reported in official labeling involve several System Organ Classes (SOCs), though specific frequency classifications are typically not applied in the standard veterinary prescribing information. Common reactions that have been observed include gastrointestinal disturbances such as vomiting, loose stools, diarrhea, and anorexia (loss of appetite). Additionally, reactions affecting the skin, such as skin eruptions, are documented.

Serious Safety Considerations

The official labeling notes the potential for serious adverse reactions. These include blood dyscrasias, such as non-regenerative anemia and thrombocytopenia. Furthermore, the risk of ocular toxicity is identified, specifically keratoconjunctivitis sicca (KCS), a condition that can result in permanent eye damage.

Population-Specific and Contextual Restrictions

Regulatory documents outline specific safety constraints. The medication is contraindicated in animals with a known hypersensitivity to any component, including sulfonamides or ormetoprim. Use is not recommended in patients with pre-existing marked liver damage or blood abnormalities. Caution is advised for patients with impaired renal function due to the potential for crystalluria. The safety of Primor has not been established for use in pregnant or nursing animals. It is also documented that certain serious effects, like KCS, are associated with long-term exposure to the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

In cases of suspected or witnessed overdose of Primor, immediate contact with a veterinarian or an animal poison control center is the mandatory action as defined in regulatory documentation. This response is required because the official prescribing information documents that excessive exposure may lead to severe, dose-related toxic manifestations.

Documented Overdose Presentations

Documented clinical presentations include severe neurologic disorders, such as ataxia and seizures, significant gastrointestinal distress, including vomiting and diarrhea, and systemic signs such as jaundice (yellowing of tissues) or fever. Severe manifestations of toxicity may involve life-threatening blood disorders, specifically hemolytic anemia and other blood dyscrasias, as well as damage to the liver (hepatitis) and kidneys (crystalluria). The risk of severe toxicity is noted to be elevated in patients with pre-existing liver parenchymal damage, blood cell problems, or dehydration.

Official Management Procedures

Management of an overdose relies entirely on symptomatic and supportive treatment, as no specific antidote is known or listed in regulatory materials. Given the potential for organ toxicity, continuous monitoring of hepatic function and blood cell status is necessary. The official guidance requires seeking urgent medical attention upon noting severe signs such as jaundice, collapse, or any serious signs indicative of toxicity.

Therapeutic Uses of Primor

What Primor Treats: Main Uses and Benefits

This medication is commonly used to help with conditions presenting with acute bacterial infections in companion animals, and is applied across domains where additional symptomatic support is needed.

Primor is relevant for managing symptoms associated with bacterial infections of the skin and soft tissues (including infected wounds and abscesses) and susceptible urinary tract infections (such as cystitis). The primary therapeutic benefit contributes to easing the overall symptom load by managing the susceptible bacterial cause of the illness. This antiinfective approach is applied in contexts where a robust systemic effect is needed to address symptom clusters related to inflammatory or irritative states, such as localized swelling, purulent discharge, or painful and frequent urination. The therapy is relevant when supportive symptom management is appropriate during these acute episodes.

Quick Fact: Relief for Acute Bacterial Discomfort

“The medication is commonly used to provide supportive relief during difficult episodes of acute bacterial infection.”

The overall supportive effect assists with maintaining functional stability and contributes to improved comfort during symptomatic periods.

Regulatory References

U.S. Code of Federal Regulations

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Primor

This medicine is a prescription-only combination antibiotic whose regulatory profile strictly defines which populations are eligible for use, based on governmental labeling. All official use is restricted to the target species, dogs.

Absolute Non-Eligibility (Contraindications)

According to regulatory documents, Primor must not be used in any dog that falls into the following categories:

Dogs with a history of sulfonamide hypersensitivity (allergy to sulfa drugs).
Dogs exhibiting marked liver parenchymal damage.
Dogs with documented blood dyscrasias.

Population Limitations and Restrictions

Category	Regulatory Status
Non-Target Species (e.g., Cats)	Excluded; for use in dogs only
Breeding, Pregnant, or Lactating Dogs	Safety in breeding dogs has not been established
Dogs with Acid Urine	Requires conditional use, including monitoring urine samples and maintaining adequate water intake to avoid crystal formation

The eligibility structure establishes clear boundaries for use by prohibiting administration to animals with specific high-risk conditions, while restricting use in populations where formal safety data is not established.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The regulatory profile for Primor (Sulfadimethoxine/Ormetoprim) outlines specific interaction patterns based on the inherent properties of the potentiated sulfonamide class, focusing on pharmacodynamic effects and the risk of altered drug exposure.

Documented Pharmacodynamic Interactions

Interacting Agent Type	Interaction Description (Official Statement)
PABA Derivatives (e.g., Procaine, Lidocaine)	Co-administration may antagonize the antibacterial action of the sulfonamide component.
Folic Acid Antagonists (e.g., Methotrexate, Pyrimethamine)	Co-administration carries the risk of potentiating adverse effects due to additive inhibition in the folic acid pathway.

Exposure and Absorption Interactions

Specific substances are noted for their potential to modify drug levels or absorption. Co-administration with cyclosporine may result in decreased plasma levels of the immunosuppressant agent. Additionally, mineral-containing substances, such as antacids, may interfere with the oral absorption of Primor's active ingredients, implying a need for temporal separation, though a specific time window is not officially mandated.

Co-administration Cautions

Specific classes of medications, including certain blood pressure medications and diuretics, are identified in regulatory guidance as substances to be used with caution during co-administration due to documented interaction potential. The medication is officially stated to not require timing separation with food.

Mechanism of Action

How Primor Works

Primor is a combination antibiotic that works by a mechanism of action called sequential blockade, which results in the interruption of the pathogen's metabolic processes. The drug's mechanism relies on the fact that bacteria must synthesize folic acid (THF), a requirement that is unique to bacterial metabolism.

Dual-Targeted Inhibition of Folic Acid Synthesis

This mechanism targets two distinct and consecutive enzymes in the bacterial metabolic pathway responsible for producing the critical co-factor, THF. Sulfadimethoxine acts first by competitively inhibiting the enzyme dihydropteroate synthase (DHPS). This initial molecular action is immediately followed by Ormetoprim inhibiting the enzyme dihydrofolate reductase (DHFR).

Synergistic Metabolic Blockade

The sequential action of the two ingredients is synergistic—meaning their combined effect is more pronounced than the effect of each drug alone. By blocking THF production, the drug cuts off the supply of precursors needed for the synthesis of DNA and RNA within the pathogen. This metabolic interference leads directly to the core physiological consequence: the arrest of bacterial replication and cell division (bacteriostasis).

Dosage and Administration Information

How Primor is Used

Primor (sulfadimethoxine/ormetoprim) is a combination antibiotic administered exclusively via the oral route as scored tablets. The tablets are available in four strengths, ranging from 120 mg to 1200 mg, which contain the active ingredients in a precise 5:1 ratio. The primary mechanism for proper use is a structured, weight-based dosing protocol that dictates both the initial amount and the maintenance schedule.

Official Dosing Protocol

Administration follows a two-part daily regimen based on body weight:

Administration Stage	Required Dose (per lb of body weight)	Frequency
Initial Loading Dose (Day 1)	25 mg	Once
Maintenance Dose (Subsequent Days)	12.5 mg	Once Daily

Following the loading dose, the medication is administered once daily. The use of scored tablets allows the dose to be accurately adjusted according to the required milligrams per pound calculation. The medication may be given with or without food.

Course Duration and Use Constraints

Treatment must be maintained for a period defined by the response to the drug. Administration must continue for at least two days after the observed remission of clinical signs. However, the total course of therapy must not exceed 21 consecutive days. The tablets are restricted by federal law for use only by or on the order of a licensed veterinarian.

Recent Clinical Evidence

Research evidence / Overview of studies for Primor

Evidence for Use in Acute Skin and Soft-Tissue Infections

The body of research evaluated for Primor (Sulfadimethoxine/Ormetoprim) in acute bacterial infections of the skin and underlying soft tissues is based on several types of investigations. These include Controlled Efficacy Studies, where the drug's components were compared under controlled conditions, and real-world Field Efficacy Trials involving the target species with naturally occurring infections. The research examined comparing the therapeutic patterns of the combined drug against its individual components, Sulfadimethoxine or Ormetoprim, when used alone.

In these studies, researchers primarily monitored two types of outcomes: Clinical Efficacy, which involved observing the physical changes in the infection site, such as the resolution status of wounds or abscesses; and Bacteriological Response, which involved testing whether the identified bacterial pathogen was cleared or persisted. The findings describe patterns observed in the studies that informed regulatory conclusions regarding the response observed with the combination against the susceptible pathogens studied. The long-term effects are not fully established, and there is limited information for long-term outcomes such as rates of recurrence.

Evidence for Use in Acute Urinary Tract Infections (Cystitis)

For acute lower urinary tract infections (such as cystitis), the evidence base consists mainly of Field Efficacy Trials that was evaluated in the target species presenting with infections caused by susceptible organisms. The research monitored specific outcomes related to systemic or functional imbalance, such as observing changes in clinical signs like painful or frequent urination. Additionally, trials measured the Bacteriological Response to determine the presence and clearance of the causative pathogen in urine culture.

This evidence contributed to defining the susceptible pathogens studied in the research and is relevant to the approved indications. While the evidence provides a basis for the drug's use in these acute conditions, data for certain groups remain insufficient outside of the primary target species studied in the field trials. The follow-up durations were limited in the main efficacy trials, leading to a lack of characterization for long-term outcomes or recurrence prevention.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Primor (FAQ)

Q: Is Primor an antibiotic, and how is it different from common antibiotics?

Primor is officially classified as a potentiated sulfonamide and a combination antibiotic. This means it contains two active ingredients that work together to interrupt the bacterial production of folic acid. This dual action and pharmacological class distinguish its mechanism from many single-ingredient antibiotics.

Q: Are there any specific foods or drinks that should be avoided while on Primor?

Official labeling states that Primor can be given with or without food. Regulatory information notes that mineral-containing substances, such as antacids, may interfere with the absorption of the active ingredients.

Q: Can Primor be used during pregnancy?

The medication is restricted for use in dogs only. Official product information states that safety has not been established for use in breeding, pregnant, or nursing animals.

Q: What is the full list of conditions Primor is officially approved to treat?

Primor is officially indicated for acute skin and soft-tissue infections (such as wounds and abscesses) caused by specific susceptible strains of Staphylococcus aureus and Escherichia coli. It is also approved for acute urinary tract infections caused by specific susceptible strains of E. coli and Staphylococcus spp. in dogs.

Q: Can Primor be taken by older adults, or are there special cautions?

The medication is approved only for use in dogs. Official regulatory documents advise caution for use in pets who are old, weak, or frail, and for those with pre-existing impaired renal (kidney) or liver function.

Q: What are the most common side effects mentioned in patient discussions about Primor?

Official labeling lists observed reactions as gastrointestinal disturbances, including vomiting, loose stools, diarrhea, and loss of appetite (anorexia). The standard regulatory information typically does not provide specific frequency classifications like 'most common'.

Q: Is it common to feel stomach upset after taking Primor?

The official documentation notes that gastrointestinal disturbances are among the observed adverse reactions, which include vomiting, loose stools, and diarrhea.

Q: Does Primor cause sensitivity to the sun?

Primor belongs to the sulfonamide drug class. Regulatory documents for related sulfonamide compounds describe an association with photosensitivity. This condition involves an increased sensitivity to sunlight that can lead to an adverse reaction.

Q: Is Primor safe for people who have kidney issues?

The medication is restricted for use in dogs only. Official documents advise caution for use in patients with impaired renal (kidney) function due to the potential for crystalluria. Crystalluria is the formation of crystals in the urinary tract.

Q: Is Primor used for anything besides bacterial infections?

No. The general purpose of Primor is to provide broad-spectrum antibacterial activity against susceptible pathogens. Its mechanism of action specifically targets the metabolic processes unique to bacteria.

Q: Can someone take Primor if they are allergic to sulfa drugs?

The medication is restricted for use in dogs only. Primor is contraindicated (must not be used) in any dog with a known hypersensitivity or allergy to any of its components, including sulfonamides (sulfa drugs).

Q: Why does the drug information warn about G6PD deficiency and Primor?

Primor is a sulfonamide-containing drug. Regulatory guidance for this drug class notes that in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, sulfonamides have been associated with the risk of acute hemolytic anemia (a type of red blood cell breakdown).

Q: What should a patient do if they develop a rash while taking Primor?

The drug is restricted for use in dogs only. Official labeling notes the potential for skin eruptions. Regulatory documents for related sulfonamide products describe that discontinuation is indicated at the first appearance of a rash or sign of a serious adverse reaction.

Q: Does Primor cause drowsiness or affect the ability to drive?

The official veterinary labeling for Primor does not list drowsiness or CNS impairment as a primary adverse reaction. However, regulatory documentation for the wider sulfonamide drug class notes that central nervous system (CNS) effects such as headache and lethargy have been observed.

Q: Can Primor affect blood sugar levels?

The sulfonamide component of Primor is chemically similar to some oral medications used to lower blood sugar. Regulatory documents for related sulfonamide products indicate that hypoglycemia (low blood sugar) has been reported in association with the use of sulfonamides.

Q: Why is hydration often mentioned when taking Primor?

Official restrictions for use in dogs with acid urine mention maintaining adequate water intake and monitoring. This is advised to help avoid the potential for crystal formation (crystalluria) in the urinary tract.

Q: Is Primor considered a broad-spectrum antibiotic?

Yes. Primor is described in official documents as possessing broad-spectrum antiinfective activity against susceptible pathogens.

Q: How does Primor relate to the combination drug 'Co-trimoxazole'?

Primor is a combination of sulfadimethoxine and ormetoprim. Co-trimoxazole is a similar drug that combines sulfamethoxazole and trimethoprim. Both drugs utilize the strategy of a potentiated sulfonamide to target the bacterial folic acid synthesis pathway.

Q: Are there long-term side effects associated with Primor use?

Official documentation notes that certain serious effects are associated with long-term exposure to the medication. This includes ocular toxicity, specifically Keratoconjunctivitis Sicca (KCS), a condition that can result in permanent eye damage.

Q: What happens if a dose of Primor is missed?

Official administration guidelines for this product describe the procedure for a missed dose as administering the dose when remembered, then resuming the regular schedule while ensuring two doses are not given simultaneously.

Q: Is Primor effective against all types of bacterial infections?

No. Primor provides activity against susceptible pathogens only. The official indications list the specific organisms for which efficacy has been established.

Q: Does Primor help with viral infections?

Based on its classification as an antibiotic and antiinfective agent, Primor's specific mechanism of action targets the metabolic pathway of bacteria. It is not indicated for use against viral infections.

Q: What are the official warnings about potential liver problems with Primor?

The drug is contraindicated (must not be used) in dogs with pre-existing marked liver parenchymal damage. Severe liver inflammation has also been noted in regulatory documentation as a potential serious side effect.

Q: Is Primor a strong antibiotic?

The drug is officially classified as a potentiated sulfonamide. This classification means that its two active ingredients are combined to work synergistically, producing an enhanced effect compared to either ingredient used alone.

Q: Has there been recent research on new uses for Primor?

Regulatory documents detailing the body of evidence focus on research that established the approved uses. Official information does not describe any research concerning new indications.

Q: How does the concentration of the drug in the body change over time?

Official documents for the sulfonamide component (Sulfadimethoxine) describe a prolonged half-life of approximately 13 hours in dogs. This extended half-life supports the once-daily maintenance dosing schedule.

Q: Does Primor cause headaches frequently?

Headaches are not listed in the common or serious adverse reaction sections of Primor’s veterinary label. However, headaches have been reported in regulatory documentation for related sulfonamide products used in humans.

How should Primor be stored and disposed of?

How to Store and Dispose of Primor

Primor tablets must be stored at controlled room temperature, specifically maintained between 15 C and 30 C (59 F and 86 F). The medication requires storage in a cool, dry, well-ventilated area and must be kept in a tight container, protected from moisture and direct sunlight. Storage near strong oxidizers or conditions that may generate heat must be avoided.

For safety, the product must be kept out of reach of children and pets at all times.

Disposal must adhere to all local and national regulations. Unused or expired medication should not be flushed down the toilet or washed down the sink. If no local take-back program is available, the product should be mixed with an undesirable substance before disposal in the regular trash to ensure environmental release is avoided.

Primor